Clinical trial
An Open-Label, Single-Arm, Multicenter, Prospective, Phase 4, Interventional, Flexible Dose Study to Evaluate the Effectiveness of Vortioxetine on Goal Achievement After a Change in Antidepressant Medication for the Treatment of Subjects With Major Depressive Disorder
NCT02972632 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Single-Arm, Multicenter, Prospective, Phase 4, Interventional, Flexible Dose Study to Evaluate the Effectiveness of Vortioxetine on Goal Achievement After a Change in Antidepressant Medication for the Treatment of Subjects With Major Depressive Disorder
- Lead sponsor
- Takeda
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 22, 2016
- Completion date
- February 6, 2018
- Enrollment
- 123 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.